Edison's orphan drug (EPI-743) misses the mark in Phase II (Rett syndrome)

Edison's orphan drug (EPI-743) misses the mark in Phase II (Rett syndrome). FierceBiotech (Daily Biotech Industry Newsletter), September 4, 2014

Despite the setback, the biotech is still chugging along with mid-stage studies to chart EPI-743's potential in its lead indications, the rare CNS ailments Friedreich's ataxia and Leigh syndrome.